AU2024249503A1 - Meningococcal protein based vaccine formulations and methods for manufacturing thereof - Google Patents

Meningococcal protein based vaccine formulations and methods for manufacturing thereof

Info

Publication number
AU2024249503A1
AU2024249503A1 AU2024249503A AU2024249503A AU2024249503A1 AU 2024249503 A1 AU2024249503 A1 AU 2024249503A1 AU 2024249503 A AU2024249503 A AU 2024249503A AU 2024249503 A AU2024249503 A AU 2024249503A AU 2024249503 A1 AU2024249503 A1 AU 2024249503A1
Authority
AU
Australia
Prior art keywords
fhbp
range
protein
seq
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024249503A
Other languages
English (en)
Inventor
Dattatreya Sarma Annamraju
Rajeev Mhalasakant DHERE
Sambhaji Shankar PISAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serum Institute of India Pvt Ltd
Original Assignee
Serum Institute of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute of India Pvt Ltd filed Critical Serum Institute of India Pvt Ltd
Publication of AU2024249503A1 publication Critical patent/AU2024249503A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2024249503A 2023-03-24 2024-03-22 Meningococcal protein based vaccine formulations and methods for manufacturing thereof Pending AU2024249503A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202321021121A IN202321021121A (https=) 2023-03-24 2023-03-24
IN202321021121 2023-03-24
PCT/IN2024/050300 WO2024201502A1 (en) 2023-03-24 2024-03-22 Meningococcal protein based vaccine formulations and methods for manufacturing thereof

Publications (1)

Publication Number Publication Date
AU2024249503A1 true AU2024249503A1 (en) 2025-10-16

Family

ID=92903953

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2024249503A Pending AU2024249503A1 (en) 2023-03-24 2024-03-22 Meningococcal protein based vaccine formulations and methods for manufacturing thereof

Country Status (12)

Country Link
EP (1) EP4687967A1 (https=)
JP (1) JP2026511179A (https=)
KR (1) KR20250166279A (https=)
CN (1) CN121038809A (https=)
AR (1) AR132199A1 (https=)
AU (1) AU2024249503A1 (https=)
IL (1) IL323559A (https=)
IN (1) IN202321021121A (https=)
MX (1) MX2025011286A (https=)
TW (1) TW202444740A (https=)
UY (1) UY40678A (https=)
WO (1) WO2024201502A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025224732A1 (en) * 2024-04-26 2025-10-30 Techinvention Lifecare Private Limited Meningococcal hexavalent combination vaccine
CN119925588B (zh) * 2025-04-08 2025-07-01 北京华诺泰生物医药科技有限公司 基于gE/pORF7双抗原纳米晶与智能相变佐剂的重组带状疱疹疫苗
CN120227449A (zh) * 2025-05-21 2025-07-01 苏州聚微生物科技有限公司 B群脑膜炎球菌疫苗组合物及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596240B (zh) * 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
EP2970920B1 (en) * 2013-03-15 2018-04-25 The Children's Hospital of Philadelphia Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
CN110804102B (zh) * 2019-11-08 2021-07-20 苏州微超生物科技有限公司 B群脑膜炎球菌疫苗及其制备方法与应用

Also Published As

Publication number Publication date
AR132199A1 (es) 2025-06-04
JP2026511179A (ja) 2026-04-10
MX2025011286A (es) 2025-11-03
CN121038809A (zh) 2025-11-28
KR20250166279A (ko) 2025-11-27
WO2024201502A1 (en) 2024-10-03
TW202444740A (zh) 2024-11-16
IN202321021121A (https=) 2024-04-19
IL323559A (en) 2025-11-01
EP4687967A1 (en) 2026-02-11
UY40678A (es) 2024-10-15

Similar Documents

Publication Publication Date Title
AU2024249503A1 (en) Meningococcal protein based vaccine formulations and methods for manufacturing thereof
US9567377B2 (en) Immunogenic composition
JP6786394B2 (ja) 改変髄膜炎菌ｆＨｂｐポリペプチド
EP3169357B1 (en) Modified meningococcal fhbp polypeptides
AU2021392894B2 (en) Donor strand complemented fimh
CN110563818A (zh) 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
TW201902921A (zh) 脂化之肺炎鏈球菌抗原組合物、製備方法及用途
CN107823638B (zh) 一种b群脑膜炎球菌重组嵌合蛋白疫苗及其制备方法
US10293041B2 (en) Multivalent stable vaccine composition and methods of making same
OA22209A (en) Meningococcal protein based vaccine formulations and methods for manufacturing thereof.
US20230414738A1 (en) Haemophilus influenzae vaccine and methods of use
WO2016007797A1 (en) Multivalent stable vaccine composition and methods of making same